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Abstract
Purpose:  Tendinopathy  is  a  frequent  and  ubiquitous  disease  developing  early  disorganized  col-
lagen ﬁbers  with  neo-angiogenesis  on  histology.  Peritendinous  injection  of  corticosteroid  is  thePlatelet;
PRP;
US
commonly  accepted  strategy  despite  the  absence  of  inﬂammation  in  tendinopathy.  Platelet-rich
plasma (PRP)  might  be  a  useful  strategy  to  rapidly  accelerate  healing  of  the  tendinopathy  but
there is  a  lack  ok  knowledge  about  the  amount  of  PRP  to  be  injected  and  the  opportunity  of  a
second injection  in  case  of  partial  pain  relief.  The  aim  of  our  study  was  to  assess  the  potential
therapeutic  effect  of  early  second  PRP  intra-tendinous  to  treat  persistent  painful  tendon  tear
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and  tendinosis  in  a  long-term  follow-up  by  ultrasonography  (US)  and  clinical  data  in  case  of
incomplete  efﬁciency  of  ﬁrst  PRP  treatment  injection.
Materials  and  methods:  Twenty-four  consecutive  patients  referred  for  US  treatment  of  tendon
tear or  tendinosis  (T+)  were  included  retrospectively.  All  had  previously  received  a  single  intra-
tendinous  injection  of  PRP  under  US  guidance  (PRPT+)  and  beneﬁted  of  a  second  PRP  injection
(PRPT2+)  under  US  guidance  in  order  to  treat  persistent  painful.  US  and  clinical  data  were
collected  for  each  anatomic  compartment  for  upper  and  lower  limbs  before  treatment  (D0),
6 weeks  (W6)  after  ﬁrst  treatment,  6  weeks  (W12)  after  second  treatment  and  until  32-month
follow-up.  We  used  Mac  Nemar  test  and  regression  model  to  compare  US  and  clinical  data.
Results: The  residual  US  size  of  lesions  was  not  signiﬁcantly  lower  at  W12  after  PRPT2+  as  com-
pared to  W6  (P  =  0.86  in  upper  and  P  =  NS  in  lower  member)  independently  of  age  (P  =  0.22),
gender (P  =  0.97)  and  kind  of  tendinopathy  (P  =  NS).  Quick  dash  test  values  and  WOMAC  values
were not  signiﬁcantly  lower  in  PRPT+  at  W12  (average:  21.5  months)  as  compared  to  W6
(P >  0.66)  and  long-term  follow-up  (P  >  0.75)  independently  of  age  (P  =  0.39),  gender  (P  =  0.63)
and kind  of  tendinopathy  (P  =  NS).  Nevertheless,  comparison  between  D0  and  long-term  follow-
up (LTF)  functionnal  score  was  statistically  signiﬁcant  (p<0.001  in  upper  and  lower  member).
Conclusion:  Our  study  suggests  that  second  early  intra-tendinous  PRP  injection  under  US
guidance does  not  permit  rapid  decrease  of  tendinopathy  area  in  US,  nor  does  it  quickly  improve
clinical pain  and  functional  data  in  case  of  incomplete  efﬁciency  of  ﬁrst  PRP  injection.  However,
in long-term  follow-up,  patients  improved  their  ability  to  mobilize  pathologic  tendons.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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uendon  tear  and  tendinosis  is  a  very  common  and  disabling
ondition,  resulting  in  impairment  of  quality  of  life.  Indeed,
endinopathy  of  the  rotator  cuff  affects  3—20%  of  the  gene-
al  population,  mainly  women  between  40-  and  65-year-old
hereas  Achilles’  tendinopathy  affects  5—6%  of  the  general
opulation,  especially  young  men.  In  most  cases,  it  pro-
resses  to  a  disabling  pain  and  cessation  of  activities  [1,2].
Healthy  tendon  is  made  up  of  type  1  collagen  and  elastin
bers,  within  an  extracellular  matrix  formed  by  tenocytes,
enoblastes  and  water.  In  case  of  tendinopathy,  histology
hows  thinned  and  disorganized  collagen  ﬁbers,  mucoid
nd/or  lipoid  degeneration  and  increased  inter-ﬁbrillar
lycosaminoglycan  deposition  [3,4].  In  addition  to  these
esions,  neo-angiogenesis  associating  neo-vessels  and  nerve
bers  development  are  constantly  reported  at  the  beginning
f  tendinopathy  and  during  tendon  healing  [5—10]. Several
ines  of  research  have  been  explored  for  the  treatment  of
endon  tear  or  tendinosis,  including  ultrasound  (US)-guided
enestration  or  tenotomy  [11—14],  hyperosmolar  solutions
14],  bone  morphogenic  protein  [15],  or  platelet-rich  plasma
PRP)  intra-tendinous  injections,  with  varying  efﬁciencies
16—23].
Despite  these  potential  treatments,  peritendinous  injec-
ion  of  corticosteroid  remains  the  commonly  accepted
trategy  to  treat  tendinopathy  [24],  despite  the  absence  of
nﬂammation  in  tendinopathy,  and  proven  tendon  damage
ue  to  intra-tendinous  injection  [25,26].
PRP  is  deﬁned  as  serum  with  three  to  eight  more  platelet
oncentration  than  blood,  which  allows  disposing  of  more
mportant  concentration  of  active  growth  factors  (PDGF,
GF-ß,  VEGF. .  .) stimulating  healing.  PRP  promotes  stem
ells  recruitment  and  stimulates  directly  collagen  produc-
ion  by  the  ﬁbroblast  of  tendon  with  proliferation  and
ifferentiation  of  human  tenocytes  and  plays  a  central  role
n  tendon  regeneration.  To  our  knowledge,  there  have  been
nly  few  studies  so  far  evaluating  the  clinical  efﬁcacy  of  PRP
6
b
Tnjections  with  long-term  follow-up.  Strategies  of  treatment
ften  vary  and  less  is  known  about  the  dose  to  be  injected
nd  the  interest  of  a  second  PRP  injection  in  case  of  partial
ain  relief.
The  aim  of  our  study  was  to  assess  the  potential  thera-
eutic  effect  of  early  second  PRP  intra-tendinous  injection
o  treat  tendon  tear  and  tendinosis  in  case  of  persistent  pain
espite  a  ﬁrst  PRP  intratendinous  injection.
aterials and methods
atients
his  monocentric  retrospective  study  was  performed  from
anuary  2010  to  September  2012.  Twenty-four  consecutive
mbulatory  patients  with  degenerative,  micro-traumatic  or
raumatic  tendinopathy  (T+)  as  tendon  tear  or  tendinosis
ere  referred  to  our  institution  for  US-guided  PRP  injection.
ain  history  and  clinical  data  using  Quick  Dash  test  (QD)  for
pper  limbs  and  Western  Ontario  and  Mac  Master  Universities
steoarthritis  Index  (WOMAC  test)  for  lower  limbs  and  Visual
nalogic  Score  (VAS  score)  were  noted.  US  assessment  of
endinopathy  was  performed  at  Day  0  (D0)  and  was  followed
y  PRP  intra-tendinous  injection  in  tear  or  tendinosis  area
nder  US  guidance  (PRPT+).
The  same  US  and  clinical  control  was  systematically  per-
ormed  6 weeks  later  (W6).  Patients  who  had  no  pain  relief
r  persistent  pain  over  3  on  VAS  score  and  remaining  tendon
bnormalities  on  US  at  W6,  independently  of  tendon  lesion
ize  or  functional  score,  beneﬁted  of  a  second  PRP  injection
nder  US  guidance  (PRPT2+).
The  same  US  and  clinical  control  was  also  performed
 weeks  later  (W12).  All  these  procedures  were  performed
y  a senior  musculoskeletal  radiologist  (LP,  PM,  AS,  BD).
he  exclusion  criteria  were  in  contraindication  to  injection
s
i
s
S
S
(
t
c
P
t
R
P
T
w
2
w
t
i
(
o
l
n
s
a
i
o
s
E
T
w
p
r
fPRP  as  a  useful  strategy  to  heal  tendinopathy  
under  US  guidance  (pregnancy,  infectious  arthritis,  previous
corticosteroid  local  injection),  acquired  or  induced  immu-
nodeﬁciency.  There  were  no  age  or  sex  inclusion  criteria.
Among  the  eligible  patients,  none  had  exclusion  criteria.
All  patients  were  informed  of  the  study  procedure  and  gave
their  informed  consent.
Platelet-rich plasma preparation
For  PRP  preparation,  the  patient  was  referred  to  a  biolo-
gist  doctor  (AP).  A  sample  of  27  mL  of  venous  blood  was
collected  in  a  syringe  containing  3  mL  of  ACD-A  anticoag-
ulant  and  was  centrifuged  at  620  g  during  15  min.  A  ﬁnal
volume  of  3  mL  of  PRP  was  recuperated  in  the  middle  part
of  plasma.  The  obtained  PRP  had  a  platelet  concentration
equal  to  about  three  times  the  concentration  measured  in
the  blood  as  veriﬁed  counting  platelets  under  an  optical
microscope  for  40  patients  (900.000  ±  15.000  platelets  per
mm3).  Leukocytes  were  also  measured  (255  ±  35  per  mm3).
PRP  (without  activator)  was  injected  within  30  min  at  the
end  of  centrifugation.
Ultrasonography
All  patients  had  US  evaluation  with  a  17  MHz  linear  probe
using  mode  B-mode  (IU  22  Philips  Medical  Healthcare
Amsterdam,  Netherlands)  to  conﬁrm  tendon  tear  or  tendi-
nosis.  Loco-regional  anesthesia  was  performed  using  1  mL  of
1%  Xylocaïne® within  the  subcutaneous  fat.  Tendon  puncture
were  performed  under  US  guidance,  with  a  21  G  intra-
muscular  needle  (LP,  PM,  AS,  BD).  After  conﬁrmation  of
intra-tendinosis  or  tear  position  of  the  needle,  we  injected
3  cm3 of  PRP  mixture  in  ﬁrst  and  second  PRP  treatment
(PRPT+  and  PRPT2+)  (Fig.  1).
Image interpretation and clinical data
All  the  images  were  anonymized  and  the  date  of  exami-
nation  was  hidden.  All  pre-  and  post-therapeutic  US  were
interpreted  by  a  senior  musculoskeletal  radiologist  (BD)  in
random  patient  order.  We  used  a  pre-written  reading  grid,
recording  for  each  anatomic  compartment  lesion  type  (tear
or  tendinosis),  size  of  the  lesion  on  T+  at  D0  (baseline),  on
PRPT+  at  W6  and  on  PRPT2+  at  W12.
Clinical  data  assessment  at  D0  before  PRP  treatment,  W6,
W12  and  on  long-term  32-month  used  QD  [27]  for  upper  limbs
and  WOMAC  test  [28]  for  lower  limbs  to  calculate  a  global
t
(
t
Figure 1. Ultrasound image of lateral epicondylar tendon (long axis) sh
injection using a 25 G needle (arrowheads).873
core,  VAS  score  and  only  one  binary  (yes  or  not)  subjective
ndex  satisfaction  for  both  are  collected.  Others  treatments,
uch  as  inﬁltration  or  surgery,  were  noted.
tatistical methods
tatistical  analysis  was  performed  using  the  SAS  software
Cary,  NC).  Binary  variables  were  tested  with  the  Mac  Nemar
est.  Differences  on  lesion  size  in  tear  or  tendinosis  were
ompared  using  the  Wilcoxon  test.  Then,  the  evolution  of
RPT+  was  assessed  using  a  Friedman  test.  A  P  value  less
han  0.05  was  considered  as  signiﬁcant.
esults
opulation data
wenty-four  consecutive  patients  (20  men  and  4  women)
ere  included  in  this  study  from  January  2010  to  September
012  with  an  average  follow-up  of  21.5  months.  Mean  age
as  47.2  ±  12.4  years  and  median  age  was  46  years.  Seven-
een  lesions  out  of  the  17  patients  (14  men  and  3  women)
nvolved  the  upper  limb  [lateral  epicondylar  tendons:  n  =  15
88%),  medial  epicondylar  tendons:  n  =  2  (12%)]  and  seven
ut  of  the  seven  patients  (6  men  and  1  women)  involved  the
ower  limb  [Achilles  tendon:  n  =  3  (43%),  patellar  tendon:
 =  2  (29%),  peroneal  tendons:  n  =  2  (29%)].
Before  ﬁrst  PRP  injection,  the  average  length  of  time  for
ymptoms  was  5.3  ±  1.7  months.
Previous  treatments  consisted  in  rehabilitation  using
nalgesic  physiotherapy  and  eccentric  work.  Corticosteroid
njection  was  an  exclusion  criteria.
No  additional  treatment  was  used  between  ﬁrst  and  sec-
nd  PRP  injection.  Besides  transitory  local  pain,  no  major
ide  effects  or  complications  were  encountered.
fﬁcacy of PRP2+ to treat PRPT+: US data
he  mean  US  size  of  lesions  for  upper  and  lower  member
ere  not  signiﬁcantly  lower  at  W12  after  PRPT2+  as  com-
ared  to  W6  (P  =  0.86  in  upper  and  P  =  NS  in  lower  member),
espectively  for  lateral  epicondylar  tendon  lesions  (P  =  0.78),
or  medial  epicondylar  tendon  lesions  (P  =  NS);  for  patellar
endon  (P  =  0.5)  and  for  the  others  anatomic  compartments
P  =  NS)  in  the  lower  limb  (Fig.  2).
Nevertheless,  comparison  between  size  of  lesions  at  D0
o  W6,  and  D0  to  W12  were  statistically  signiﬁcant  (P  <  0.001
ows longitudinal tear (white arrows) before (a) and during (b) PRP
874  B.  Dallaudière  et  al.
Figure 2. Ultrasound image of lateral epicondylar tendon (long axis) shows longitudinal tear (arrows) before (a) and after PRP injection
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n  upper  and  lower  member).  All  these  results  were  inde-
endent  of  age  (P  =  0.22),  gender  (P  =  0.97)  and  type  of
endinopathy  (P  =  NS).
Table  1  summarizes  the  mean  and  standard  deviation  (SD)
f  tendon  lesions  for  each  anatomic  compartment.
fﬁcacy of PRP to treat PRPT+: clinical data
atients  do  not  recover  a  signiﬁcant  ability  to  mobilize
athologic  tendons  when  comparing  PRPT2+  at  W12  with
RPT+  at  W6  (P  =  0.69  for  upper  and  P  =  0.66  for  lower  limb)
nd  with  long-term  follow-up  (P  =  0.86  for  upper  and  P  =  0.75
or  lower  limb).
In upper  member,  QD  is  39.8  ±  9.4  at  D0,  17.2  ±  9.1  at
6,  14.7  ±  3.2  at  W12,  14.2  ±  4.3  at  21.5  months  of  aver-
ge  follow-up.  In  lower  member,  WOMAC  is  34  ±  12.1  at  D0,
a
b
2
Table  1  Mean  and  SD  (millimeters)  values  of  US  lesions  in  eac
0  (D0),  week  6 (W6)  and  week  12  (W12).
Upper  limb  
D0  W6  W12  
Lateral  epicondylar  tendons  8.4  ±  2.6  3.1  ±  3.8  2.7  ±  3.
Medial  epicondylar  tendons  8  ±  1.4  4.5  ±  6.4  0   remaining hyperhemia at W12 which in an usual ﬁnding at color
.4  ±  2.7  at  W6,  7.3  ±  2.2  at  W12,  6.7  ±  4.9  at  21.5  months
f  average  follow-up.
Table  2  summarizes  the  mean  and  standard  deviation  (SD)
f  functional  evaluation  in  tendon  lesions  and  each  anatomic
ompartment.
Nevertheless,  comparison  between  baseline  and  long-
erm  follow-up  functional  score  were  statistically  signiﬁcant
P  <  0.001  in  upper  and  lower  member)  and  patients
ecover  ﬁnally  a  signiﬁcant  ability  to  mobilize  pathologic
endons.
All  these  clinical  results  are  independent  of  age
P  =  0.39),  gender  (P  =  0.63)  and  kind  of  tendinopathy  (P  =  NS)
t  W12  and  on  long-term  follow-up.
VAS  score  were  also  no  statistically  signiﬁcant  (P  >  0.27)
etween  W6  and  W12:  5.8  ±  1.7  at  D0,  3.8  ±  2.2  at  W6,
 ±  0.7  at  W12,  1.4  ±  1.9  at  long-term  follow-up.
h  anatomic  compartment  in  upper  and  lower  limb  at  day
Lower  limb
DO  W6  W12
3  Achilles  tendons  9.7  ±  0.6  1.5  ±  2.6  7.5  ±  10.6
Patellar  tendons  6  ±  1.7  6.8  ±  4.6  1.3  ±  1.8
PRP  as  a  useful  strategy  to  heal  tendinopathy  875
Table  2  Mean  and  SD  values  of  functional  clinical  data  in  upper  and  lower  limb  at  day  0  (D0),  week  6  (W6),  week  12
(W12)  and  long-term  follow-up  (LTF).
Upper  limb  QuickDASH  test Lower  limb  WOMAC  test
D0  W6  W12  LTF  DO  W6  W12  LTF
Lateral
epicondylar
tendons
38.2 ±  9.7  18.1  ±  9.7  14.6  ±  3.2  14.7  ±  4.6  Achilles
tendons
36.7  ±  6.4  10.7  ±  1.5  7.7  ±  3  10.3  ±  3.2
Medial
epicondylar
tendons
44  13  17  ±  2.8  12  Patellar
tendons
15 10  7.7  ±  3  1.5  ±  2.1
Rotator  cuff 50 12  11  11  Ankle 45 5  7  ±  2.8  6
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However,  there  were  22  (92%)  patients  who  were  satisﬁed
of  the  procedure  and  PRP  treatment  on  long-term  follow-up.
None  of  the  patients  got  corticosteroid  injections  or
surgery  after  second  PRP  injection.
Discussion
Our  study  suggests  that  second  early  intra  tendinous  PRP
injection  under  US  guidance  does  not  permit  rapid  decrease
of  tendinopathy  area  in  US  nor  does  it  rapidly  improve  clini-
cal  pain  and  functional  data  in  case  of  incomplete  efﬁciency
of  a  ﬁrst  PRP  injection.  However,  our  clinical  data  also  sug-
gest  that  protocol  based  on  2  PRP  injections  is  efﬁcient  in
long  term  follow  up  as  patients  recovered  a  signiﬁcant  ability
to  mobilize  pathologic  tendons  after  PRP  injections.
Many  therapeutic  strategies  are  currently  being  eval-
uated  clinically.  Reports  assessing  autologous  blood,  PRP,
sclerotic  drugs  administrated  in  different  injection  sites
(intra-,  peritendinous)  under  different  conditions  (clinically-
guided,  imaging-guided)  on  small  populations  have  been
published.  However,  these  studies  involved  biases,  such  as
lack  of  long-term  follow-up  and  no  histological  examination
[25];  hence,  resulting  in  contradicting  conclusions.  Stud-
ies  assessing  the  efﬁcacy  of  intra-  or  peritendinous  [29—32]
or  intra-articular  PRP  injections  [33,34]  on  clinical  patients
have  also  provided  discordant  results,  with  no  consensus  on
whether  PRP  injection  should  be  used  or  not.  Consequently,
there  is  no  consensus  regarding  which  drug  to  use  in  this  indi-
cation.  By  following  patients  treated  by  PRP  with  long-term
follow-up,  including  a  systematic  clinical  and  US  examina-
tion,  our  study  provides  strong  evidence  that  PRP  might  be
a  useful  strategy.
Physiologically,  a  tendon  is  formed  by  collagen  ﬁbers,
associated  with  striated  muscle  cells  in  smaller  quan-
tities  than  in  muscle.  Histology  shows  early  anarchic
misalignment  of  muscle  cells  and  collagen  ﬁbers,  result-
ing  in  important  ﬁbrillar  disorganization  after  induction
of  tendinosis  [2].  Reports  show  no  sign  of  inﬂammation.
Regarding  neo-angiogenesis,  it  has  been  shown  that  neo-
vessels,  even  early  after  the  beginning  of  tendinosis,
carry  proteolytic  enzymes,  nitric  oxide  and  deleterious
prostaglandines  that  may  be  responsible  for  tendon  degen-
eration  [35—37].  Conversely,  later  in  the  healing  process,
these  neo-vessels  provide  active  growth  factors,  which  stim-
ulate  scarring,  and  leucocytes  recruitment  for  antibacterial
C
O
itendons
ffect.  Growth  factors  promote  stem  cells  and  stimu-
ate  directly  ﬁbroblast-mediated  collagen  production  [37].
ntra-tendinous  injection  of  PRP,  by  providing  important
oncentration  of  active  growth  factors  (PDGF,  TGF-ß,
EGF. .  .), might  promote  stem  cells  recruitment  and  ﬁbro-
last  collagen  production,  and  therefore,  stimulate  tendon
carring  [38,39].
We  acknowledge  that  our  study  have  several  limitations.
ne  should  note  that  our  injection  protocol  was  based  on
n  early  second  intra-tendinous  injection  of  PRP  [19,29]
nd  used  a  limited  platelet  concentration.  Our  results  might
ave  been  different  if  we  had  used  lower  or  higher  platelet
oncentration  and/or  repeated  intra-tendinous  injections.
uch  strategies  will  have  to  be  evaluated  in  further  studies.
Second,  US  was  only  use  to  assess  the  pathological  status
f  tendons  at  D0,  W6  and  W12,  but  not  on  long-term  follow-
p.  None  surgical  evaluation  or  MRI  were  used  to  assess  the
athological  status  of  tendons.  However,  17  MHz  US  trans-
ucers  provide  excellent  spatial  resolution  and  allow  precise
easurement  of  stretched  tendons  as  well  as  needle  guid-
nce.  We  also  voluntary  choose  US  rather  than  MRI  as  it  is  a
aster,  more  available,  cheaper  and  as  efﬁcient  for  tendon
ssessment.  Third,  our  study  is  retrospective  with  only  24
atients  and  suffers  from  the  lack  of  a  control  group  and
herefore  requires  future  conﬁrmation  and  further  studies.
ccording  to  our  experience,  we  are  conﬁdent  that  our  study
hat  includes  24  patients  offers  sufﬁcient  evidence  to  con-
lude  that  an  early  second  PRP  injection  is  useless  in  case
f  incomplete  inefﬁciency  of  ﬁrst  injection.
However,  to  our  knowledge,  this  is  the  most  important
etrospective  study  about  second  PRP  injection  efﬁcacy  with
n  exact  knowledge  of  PRP  composition  concerning  platelets
nd  leukocytes  and  reproducible  clinical  scores.  PRP  ther-
pies  are  more  complicated  than  previously  acknowledged,
nd  an  understanding  of  the  fundamental  processes  and  piv-
tal  molecules  involved  will  hopefully  be  elucidated  soon.
herefore,  major  issues,  including  standardization  of  formu-
ations  and  application  procedures,  need  to  be  clariﬁed  to
nform  clinical  studies  before  recommending  best  practice
uidelines  [40—43].onclusion
ur  study  suggests  that  second  early  intra  tendinous  PRP
njection  under  US  guidance  does  not  permit  rapid  decrease
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[76  
f  tendinopathy  area  in  US,  nor  does  it  quickly  improve  clini-
al  pain  and  functional  data  in  case  of  incomplete  efﬁciency
f  a  ﬁrst  PRP  injection.
However,  our  clinical  data  also  suggest  that  protocol
ased  on  2  PRP  injections  is  efﬁcient  in  long-term  follow-
p  as  patients  recovered  a  signiﬁcant  ability  to  mobilize
athologic  tendons  after  PRP  injections.
Additional  pre-clinical  and  clinical  studies  comparing  PRP
o  currently  used  methods  might  be  of  high  interest  to  con-
olidate  clinical  practice  in  human  [44—48].
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